Analystreport

Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) is now covered by analysts at Noble Financial. They set a "buy" rating and a $33.00 price target on the stock.

Adamas Pharmaceuticals, Inc.  (ADMS) 
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors